Cyclacel Pharma (CYCC) Reports Q3 Loss of $0.86
Tweet
Share
E-mailGet Alerts CYCC Hot Sheet
Join SI Premium – FREE
Cyclacel Pharma (NASDAQ: CYCC) reported Q3 EPS of ($0.86), versus ($0.91) reported last year. Revenue for the quarter came in at $0 , versus $0 reported last year.
For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) Tops Q2 EPS by 22c; lifrs profit guidance
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Opera Limited (OPRA) Misses Q2 EPS by 1c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
